1 / 8

American Evaluation Association EVALUATION 2011 November 3, 2011

Approaches to Biomedical Research and Development Portfolio Analysis: Examples From the National Institutes of Health Panel Session 233. American Evaluation Association EVALUATION 2011 November 3, 2011. Session Presenters. James Corrigan Chair Brian Zuckerman

isolde
Download Presentation

American Evaluation Association EVALUATION 2011 November 3, 2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Approaches to Biomedical Research and Development Portfolio Analysis: Examples From the National Institutes of Health Panel Session 233 American Evaluation AssociationEVALUATION 2011November 3, 2011

  2. Session Presenters James Corrigan Chair Brian Zuckerman Identifying the Role of Funded Research in Pivotal Cancer Research Advances Kevin Wright Estimating the Impact of Hypothetical Portfolio Reductions on Production of Major Discoveries Funded by the National Institute of Allergy and Infectious Diseases Joshua Schnell Using Multiple Methods and Data Sources to Analyze Complex Cancer Research Portfolios

  3. National Institutes of Health Office of the Director National Heart, Lung and Blood Institute National Human Genome Research Institute National Institute on Aging National Institute on Alcohol Abuse and Alcoholism National Cancer Institute National Eye Institute National Institute of Dental and Craniofacial Research National Institute on Deafness and Other Communication Disorders National Institute of Child Health and Human Development National Institute of Biomedical Imaging and Bioengineering National Institute of Arthritis & Musculoskeletal & Skin Diseases National Institute of Diabetes & Digestive & Kidney Diseases National Institute of Allergy and Infectious Diseases National Institute on Drug Abuse National Institute of Environmental Health Sciences National Institute of General Medical Sciences National Institute of Mental Health National Institute of Neurological Disorders and Stroke Fogarty International Center National Library of Medicine National Institute of Nursing Research National Center for Complementary & Alternative Medicine National Center on Minority Health & Health Disparities National Center For Research Resources Clinical Center Center for Information Technology Center for Scientific Review

  4. About the National Institutes of Health (NIH) • Primary US agency for supporting and conducting biomedical research • Invests > $30B in biomedical research • > 80% funding awarded through nearly 50,000 competitive grants to > 325,000 researchers at > 3,000 research institutions • About 10% funding supports 6,000 intramural researchers

  5. Common Uses of Portfolio Analysis • Program planning • Progress monitoring • Evaluation • Impact assessment

  6. Questions Addressed • What role has our sponsored research played in recognized basic and clinical scientific advances? • What major scientific advances might have been lost if our portfolio was reduced by various amounts? • What new technologies (e.g., drugs, biomarkers) are linked to our funded portfolio? • How might we expand our portfolio analyses with new data to more completely represent the universe of funded research in our subject area(s)?

  7. Methods Used • Retrospective analysis of expert-identified research advances: links to sponsored research (Zuckerman) • Scenario/counterfactual analysis: estimating impact of funding cuts on discoveries (Wright) • FDA-approved drugs: links to patents, publications and sponsored research (Schnell) • Biomarkers: links to publications and sponsored research (Schnell) • Funded research: linking publications to grants from multiple funders (Schnell)

  8. Data Sources • Expert-identified basic /clinical advances & underlying publications/grants (Zuckerman) • Expert-identified scientific advances & characteristics of associated grants (Wright) • FDA-approved drugs & related patents/publications/grants (Schnell) • Expert-identified biomarkers & related publications/grants (Schnell) • Funder-supplied grant data & related publications (Schnell)

More Related